Drug Trial Radar · NCT03158090
The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research
Last checked: Nov 20, 2026Latest source record: Mar 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,965
Planned (sponsor's estimate)
Start
Dec 15, 2017
Primary completion
Dec 30, 2050
Study completion Jan 30, 2051
Sponsor
- Lead sponsor
- Ginkgo Leaf Center for Rare DisordersAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 17, 2017
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
Summary
As written by the sponsor on the registry.
This study is a prospective, noninteractive, observational, and longitudinal study aimed at assessing the treatment pattern and clinical outcome of acromegaly in China.
Conditions
- Acromegaly
Interventions
Transnasal butterfly surgeryProcedure
The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient.
sandostatinDrug
The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
radiotherapyRadiation
The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
Primary outcomes
What the sponsor says the trial is designed to measure.
- clinical outcome: overall survivalTime frame: 30 yeas
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China Acromegaly Organization
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.